Inflammatory

Despite the availability of current therapeutics, there remains the unmet need for more effective treatment to reduce the recurrence rate which is quite high. Emerging drugs like Mirikizumab (Eli Lilly and Company), Stelara (Janssen Research & Development, LLC), Entyvio(Takeda Oncology), and others are likely capable to eliminate the current challenges and also have the potential to drive the market size of pediatric Crohn’s Disease (pCD). The reduced cost of biosimilars relative to Pediatric Crohn’s disease can drive market competition, contributing to budget sustainability and improving patient access to biologic treatments.